Aktienanalyse zu Uniqure NV (QURE)QUREUniqure NV

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

uniQure NV (QURE) is a good buy right now, trading at $48.72 with a strong potential upside. The stock has shown a remarkable year-to-date change of +108.29% and a one-year change of +186.42%, indicating strong momentum. Additionally, the gross margin has improved significantly, reaching 94.01% in Q2 2026, which reflects efficient operations and profitability potential. The main risk is the negative earnings per share (EPS) of -1.22 reported in the last earnings call, which indicates ongoing losses, but the overall positive sentiment from analysts suggests that the stock could appreciate further as regulatory developments unfold.

5 analysts cover QURE: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 49.88.